Rigel Pharmaceuticals (RIGL) Competitor Comparison
We are evaluating the key criteria listed to compare Rigel Pharmaceuticals (RIGL) against its competitors in the Biotechnology industry.
Market Capitalization
211 / 368Gross Profits
62 / 278Total Revenue
81 / 300EBITDA
84 / 337Free Cashflow
150 / 352Quick Ratio
300 / 357Earnings per Share
48 / 359Dividend yield
0 / 5Total Cash
247 / 358Performance 3 years
233 / 368Performance 5 years
197 / 368Performance 10 years
188 / 368Linearity 3 years
188 / 368Linearity 5 years
101 / 368Linearity 10 years
124 / 368Total Rank
35 / 368Dividend Rank
264 / 368Valuation Rank
6 / 368Piotroski Rank
8 / 368Muliplier Rank
39 / 368Gross Profits - RIGL ranking 62 / 278
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.